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Abstract
Background: The newly registered adjuvanted herpes zoster subunit vaccine (HZ/su) has a higher efficacy than the
available live-attenuated vaccine (ZVL). National decision-makers soon need to decide whether to introduce HZ/su
or to prefer HZ/su above ZVL.
Methods: Using a Markov model with a decision tree, we conducted a cost-effectiveness analysis of vaccination
with HZ/su (two doses within 2 months) or zoster vaccine live (ZVL) (single dose, or single dose with a booster after
10 years) for cohorts of 50-, 60-, 70- or 80-year-olds in the Netherlands. The model was parameterized using vaccine
efficacy data from randomized clinical trials and up-to-date incidence, costs and health-related quality of life data
from national datasets. We used a time horizon of 15 years, and the analysis was conducted from the societal
perspective.
Results: At a coverage of 50%, vaccination with two doses of HZ/su was estimated to prevent 4335 to 10,896 HZ
cases, depending on the cohort age. In comparison, this reduction was estimated at 400–4877 for ZVL and 427–
6466 for ZVL with a booster. The maximum vaccine cost per series of HZ/su to remain cost-effective to a willingness-
to-pay threshold of €20,000 per quality-adjusted life year (QALY) gained ranged from €109.09 for 70-year-olds to €63.68
for 50-year-olds. The cost-effectiveness of ZVL changed considerably by age, with corresponding maximum vaccine
cost per dose ranging from €51.37 for 60-year-olds to €0.73 for 80-year-olds. Adding a ZVL booster after 10 years would
require a substantial reduction of the maximum cost per dose to remain cost-effective as compared to ZVL single dose.
Sensitivity analyses on the vaccine cost demonstrated that there were scenarios in which vaccination with either HZ/su
(two doses), ZVL single dose or ZVL + booster could be the most cost-effective strategy.
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Conclusions: A strategy with two doses of HZ/su was superior in reducing the burden of HZ as compared to a single
dose or single dose + booster of ZVL. Both vaccines could potentially be cost-effective to a conventional Dutch
willingness-to-pay threshold for preventive interventions. However, whether HZ/su or ZVL would be the most cost-
effective alternative depends largely on the vaccine cost.
Keywords: Herpes zoster, Cost-effectiveness, Vaccination, Post-herpetic neuralgia, Subunit vaccine, Live-attenuated
vaccine
Introduction
Herpes zoster (HZ) is a painful, itchy, vesicular rash with
a characteristic dermatomal distribution. It is caused by
the reactivation of latent varicella-zoster virus (VZV),
previously introduced during primary infection (vari-
cella) [1]. In the Netherlands, where varicella vaccination
has not been implemented, over 95% of the population
is infected with VZV before the age of 6 years [2]. The
average incidence of HZ in the Netherlands was 520 per
100,000 person-years in the period 2012–2015, and older
age and a compromised immune system are the most
important risk factors [1, 3, 4]. However, given the age-
ing population, it is expected that the incidence of HZ
will increase in the near future [5]. Persistent pain, la-
belled post-herpetic neuralgia (PHN), is the most com-
mon complication of HZ occurring in 3–19% of the
patients [1, 6, 7]. PHN might persist for years and is as-
sociated with significant interference with daily life activ-
ities [8, 9].
Besides the prevention by vaccination, therapeutic op-
tions for HZ and PHN are scarce. Therefore, several
countries, including the United Kingdom (UK) and
United States (US), have introduced HZ vaccination for
older adults using the existing live-attenuated vaccine
(zoster vaccine live [ZVL] or Zostavax®), which has been
registered in 2006 and was the only available vaccine at
the time of introduction of vaccination in the UK/US.
ZVL contains the live-attenuated OKA VZV strain and
is registered for immunocompetent adults aged ≥ 50
years [10]. A large randomized clinical trial among older
adults aged ≥ 60 years showed that a single dose of ZVL
was 51% (95% confidence interval [95% CI] 44–58%) ef-
ficacious against HZ and 67% (95% CI 48–79%) against
PHN [11]. However, efficacy against HZ was limited in
the eldest age groups (38% [95% CI 25–48%] among ≥
70-year-olds), and a long-term follow-up study demon-
strated that protection had completely waned within 10
years [12]. Therefore, several countries, including the
Netherlands, decided against the use of ZVL in a public
programme [13]. Nowadays, several post-licensure stud-
ies have confirmed the safety and effectiveness of ZVL.
However, the decline of effectiveness with increasing age
was less evident in post-licensure studies as compared to
the clinical trial [14–17].
A new adjuvanted HZ subunit vaccine (HZ/su or
Shingrix®) might potentially overcome the shortcomings
of ZVL. In Europe, HZ/su has been registered for all
adults aged ≥ 50 years in 2018 and is a recombinant
vaccine containing the VZV glycoprotein E adjuvanted
with the AS01B system [18]. The vaccine has been de-
veloped to be given in a two-dose schedule given 2–6
months apart. Two large randomized clinical trials have
demonstrated that the protective efficacy of two doses
HZ/su against HZ incidence was 97% (95% CI 94–99%)
among immunocompetent ≥ 50-year-olds and 91% (95%
CI 87–95%) among ≥ 70-year-olds [19, 20]. The dur-
ation of protection is currently unknown, but the trial
confirmed a relative stable efficacy over 4 years of
follow-up [20].
Due to the registration of HZ/su, governments have
the option to reassess their vaccination policy for HZ
in the near future, but cost-effectiveness analyses for
HZ/su are yet scarce. Previous cost-effectiveness
studies for the US, Hong Kong and Germany exist
[21–24]; however, results from other countries are
not directly transferable to the Dutch context due to
potential differences in epidemiological conditions,
existing vaccination policies against HZ and varicella,
healthcare resource use and relative prices. Moreover,
no comparison of HZ/su with ZVL booster strategies
has been performed, and a lack of studies incorporat-
ing real-world effectiveness data for ZVL is noticed.
Therefore, we conducted a cost-effectiveness analysis
of HZ vaccination for the Dutch setting. First, we
compared the impact of HZ/su and ZVL in immuno-
competent older adults using efficacy data from the
original vaccine trials, and we included a booster al-
ternative for ZVL as well. Next, we analysed the
threshold cost-effectiveness of HZ vaccination by
seeking the maximum vaccine cost allowed to remain
below €20,000 per quality-adjusted life year (QALY)
gained, which is the conventional cost-effectiveness
threshold for vaccination in the Netherlands [25]. As
the burden of HZ and vaccine efficacy against HZ
depends on age, we studied HZ vaccination for dif-
ferent vaccination ages and explicitly addressed the
use of ZVL post-licensure real-world effectiveness
data in a sensitivity analysis.
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Methods
Overview
A static Markov model connected with a decision tree
(Additional file 1: Figure S1) was developed in Microsoft
Excel 2010 (Microsoft Corporation, Redmond, WA,
USA) to quantify the costs and health effects (in QALYs)
of vaccination of Dutch older adults against HZ from a
societal perspective. We used a static model, as HZ is a
reactivation of an existing VZV infection, and no impact
on transmission dynamics like herd effects is expected.
Studied alternatives were (i) no vaccination (current
situation), (ii) vaccination with HZ/su (two doses within
2 months) and (iii) ZVL (single dose) and (iv) ZVL (sin-
gle dose with a booster after 10 years). We used a
10-year period for the booster, as an immunogenicity
study showed that a booster after this period is safe and
provokes a similar immunological response as a first
dose [26]. In the Markov model, cohorts were followed
in annual cycles with an age maximum of 110 years. In
each cycle, participants had the probability to stay alive
or die due to another cause. Individuals who remained
alive entered the decision tree, having the possibility
to develop HZ, which subsequently could lead to
hospitalization and/or death. We studied cohorts of
50, 60, 70 and 80 years of age. Due to the high un-
certainty around the long-term efficacy of HZ/su, we
limited the time horizon to 15 years in the base case
analysis (for instance from 70 to 85 years of age). We
chose this conservative time horizon to do justice to
the low level of decline of HZ/su efficacy within the
trial period but also to avoid overvaluation of the
impact of vaccination among this older cohort by
using a lifetime time horizon. According to the
Dutch cost-effectiveness guidelines, future costs and
QALYs were annually discounted by 4% and 1.5%, re-
spectively [27].
Epidemiology
Epidemiological inputs are shown in Table 1. Actual co-
hort sizes per January 1, 2017, and background mortality
rates were obtained from Statistics Netherlands [28, 29].
The average incidence of HZ by age over the period
2012–2015 came from the NIVEL primary care database,
a GP surveillance system covering approximately 0.7% of
the Dutch population [3, 30]. We adjusted these rates
for possible misdiagnoses by setting the proportion of
false-positive diagnoses at 10.0% (95% CI 7.9–12.4%)
[31]. Average incidence rates of HZ hospitalizations and
1-day hospital admissions by age over the period 2012–
2014 were retrieved from the Dutch Hospital Data data-
base, covering 80% of the population in 2012–2013 and
90% of the population in 2014 [32, 33]. Only admissions
with a main diagnosis of HZ (International Statistical
Classification of Diseases and Related Health Problems
[ICD] code B02) were used. The incidence of HZ-related
mortality by age was based on the number of HZ death
registries (ICD-code B02) over the period 2009–2015,
obtained from Dutch national death registries that con-
tain the cause of death of 98.5% of the deaths [34]. We
adjusted the mortality rates according to a validation
study on HZ coding of death registries in the US, indi-
cating that HZ was not the true underlying cause of
death in 47.5% (95% CI 32.0–63.0%) of the deaths
assigned to HZ [35].
QALY loss
The QALY loss per HZ case was calculated by multiply-
ing the time spent in a certain health state by the reduc-
tion of health-related quality of life (HR-QoL), i.e.
disutility, associated with that health state and is shown
in Table 1. For this calculation, we distinguished four
health states of HZ, i.e. no pain, mild pain, moderate
pain and severe pain. The proportion of patients in each
health state over time was estimated using a Dutch pro-
spective cohort study that followed HZ patients aged ≥
50 years over a maximum period of 12 months [6]. Dis-
utilities by health state over time were obtained from the
same study and were based on the validated three-level
version of the Euroqol-5 dimensions (EQ-5D-3L) instru-
ment. As severity and duration of pain showed to in-
crease by age, separate analyses were done for the age
groups 50–59 years and ≥ 60 years. Patients with moder-
ate or severe pain after 3 months were defined as PHN
patients. We found that the risk of PHN was estimated
at 2.2% for 50- to 59-year-olds and 7.3% for ≥ 60-year--
olds. More details can be found in Additional file 1. Life
years (LY) lost due to HZ-related premature mortality
were estimated using life tables and were converted to
QALYs lost using age-specific EQ-5D-3 L population
norms from the Netherlands [36]. We ignored QALY
losses due to vaccine-related adverse events in our base
case analysis, as both HZ/su and ZVL only caused
short-term symptoms, and the impact on HR-QoL was
not investigated [11, 19].
Costs
HZ-related costs per case are shown in Table 1. All costs
were adjusted to the 2017 price year using the Dutch na-
tional consumer price index [37]. Costs per HZ case
were estimated using the same prospective cohort study
that was used to estimate HZ-related QALY losses [6].
In this study, the number of GP visits, specialist refer-
rals, medication use and productivity loss was asked at
different time points and were then converted to costs
per case using standardized cost per item. Costs per hos-
pital admission were based on the length of stay of ad-
missions having HZ as main a diagnosis (ICD-code B02)
over the period 2012–2014, and cost of a 1-day visit was
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Table 1 Model inputs of the analysis. In the probabilistic sensitivity analysis, the parameter inputs were simultaneously varied within
the lower and upper estimates according to the distribution shown. In the deterministic sensitivity analysis, the parameter inputs
were varied one-by-one between lower and upper inputs, while the “scenario” column shows inputs based on other plausible
assumptions or sources
Variable Base case Lower Upper Distribution Scenario Reference (base case/scenario)
Demography
Cohort size Statistics Netherlands [29]
50 years 253,491
60 years 222,845
70 years 217,058
80 years 93,547
Background mortality Age-specific Statistics Netherlands [28]
HZ epidemiology
HZ incidence per 100,000
person-years
NIVEL [30]/incidence adjusted for
immunocompetent population using
Schroder [4]
50–59 years 591 575 607 Beta 461
60–69 years 857 835 878 Beta 669
70–79 years 1190 1157 1222 Beta 929
≥ 80 years 1481 1435 1527 Beta 1156
False positive HZ
diagnoses (%)
10.0 7.9 12.4 Beta 0 Van Hoek [31]/assuming no false positives
HZ hospitalization
incidence per 100,000
person-years
Dutch Hospital Data [32]/incidence adjusted
for the immunocompetent population using
Hobbelen [49]
50–59 years 2.5 2.1 2.9 Beta 2.2
60–69 years 4.9 4.3 5.5 Beta 4.3
70–79 years 9.5 8.4 10.6 Beta 8.3
≥ 80 years 18.4 16.4 20.4 Beta 16.1
HZ 1-day hospital admission
incidence per 100,000
person-years
Dutch Hospital Data [32]/incidence adjusted
for the immunocompetent population using
Hobbelen [49]
50–59 years 3.6 3.1 4.0 Beta 3.1
60–69 years 9.6 8.8 10.5 Beta 8.4
70–79 years 21.8 20.1 23.4 Beta 19.1
≥ 80 years 28.2 25.8 30.7 Beta 24.8
HZ mortality incidence
per million person-years
Statistics Netherlands [34]/incidence adjusted
for the immunocompetent population using
Hobbelen [49]
50–59 years 0.1 – 0.3 Beta 0.1
60–69 years 0.4 0.05 0.7 Beta 0.3
70–79 years 1.8 0.9 2.8 Beta 1.6
80–89 years 16.5 12.6 20.5 Beta 14.3
≥ 90 years 108.9 84.6 133.2 Beta 94.5
Misclassification HZ as
underlying cause of
death (%)
47.5 32.0 63.0 Beta 0 Mahamud [35]/assuming no misclassification
QALY loss
QALY loss per HZ episode Van Wijck [6]/utilities Van Hoek/QALY
loss per HZ episode Van Hoek [31]
50–59 years 0.040 0.025 0.063 a 0.034/0.067
≥ 60 years 0.057 0.039 0.093 a 0.053/0.200
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Table 1 Model inputs of the analysis. In the probabilistic sensitivity analysis, the parameter inputs were simultaneously varied within
the lower and upper estimates according to the distribution shown. In the deterministic sensitivity analysis, the parameter inputs
were varied one-by-one between lower and upper inputs, while the “scenario” column shows inputs based on other plausible
assumptions or sources (Continued)
Variable Base case Lower Upper Distribution Scenario Reference (base case/scenario)
QALY loss per HZ death Age-specific Statistics Netherlands [28], Szende [36]
QALY loss grade 3 adverse
event per dose
Excluded/QALY loss for grade 3 adverse
events (see Additional file 1)
HZ/su 0 0.000329
ZVL 0 0.000022
Costs (€, 2017)
Health care costs
GP visit, medication,
specialist visit
Based on multiple sources (see Additional file 1)
50–59 years 158 130 186 a
≥ 60 years 198 163 233 a
Hospital admission
50–59 years 2856 2490 3222 a
60–69 years 3632 3166 4097 a
70–79 years 3671 3325 4016 a
≥ 80 years 4504 4093 4915 a
One-day hospital
admission
282 Hakkaart-van Roijen [38]
Healthcare costs in
gained life years per
averted HZ death
Age-specific 0 Statistics Netherlands [28], Van Baal [40]/
excluding costs in gained life years
Vaccine administration 11.36 SNPG [41]
Patient costs
OTC medication per
HZ episode
Based on multiple sources (see Additional file 1)
50–59 years 10.42 8.85 12.00 a
≥ 60 years 12.65 10.75 14.56 a
Travel costs GP visit,
medication, specialist
care per HZ episode
Based on multiple sources (see Additional file 1)
50–59 years 3.33 2.61 4.06 a
≥ 60 years 4.07 3.19 4.95 a
Travel costs hospital
per HZ hospital visit/
hospitalization
5.79
Travel costs per
vaccination
0.43
Productivity losses
HZ episode Based on multiple sources (see Additional file 1)
50–59 years 398 230 744 a
60–69 years 136 78 262 a
≥ 70 years 0
HZ death Friction period of 84 working days [27]
50–59 years 14,937
60–69 years 5074
≥ 70 years –
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obtained from the literature [32, 38]. According to the
most recent Dutch guideline on cost-effectiveness re-
search, unrelated healthcare costs in gained life years
(i.e. indirect medical costs) should be included in the
base case analysis [39]. These costs were estimated
using the life expectancy at the age of death multiplied
with yearly age-specific healthcare costs obtained from
a specifically developed costing tool [40]. More details
on the estimated costs per HZ episode are shown in
Additional file 1. For vaccine administration costs, we
used the current Dutch influenza tariff of €11.36 per
dose, assuming that HZ vaccination would be provided
in a GP-based programme [41]. This tariff covers, next
to vaccine administration costs, costs due to patient
selection and invitation, record keeping, vaccine storage
and waste destruction.
Vaccine characteristics
Vaccine-related inputs are shown in Table 1. Given that
ZVL is contraindicated to immunocompromised indi-
viduals, we restricted vaccination in our analysis to
the immunocompetent part of the population. A re-
cent questionnaire among a random sample of Dutch
older adults aged ≥ 50 years indicated that the accept-
ance rate of vaccination against HZ was 58% [42].
Considering that the proportion of the Dutch popula-
tion that is immunocompromised ranges from 1.9% in
50- to 64-year-olds to 11.5% in ≥ 85-year-olds [43], we
Table 1 Model inputs of the analysis. In the probabilistic sensitivity analysis, the parameter inputs were simultaneously varied within
the lower and upper estimates according to the distribution shown. In the deterministic sensitivity analysis, the parameter inputs
were varied one-by-one between lower and upper inputs, while the “scenario” column shows inputs based on other plausible
assumptions or sources (Continued)
Variable Base case Lower Upper Distribution Scenario Reference (base case/scenario)
Vaccine characteristics
Vaccine uptake (%) 50 Assumption based on Eilers [42]
Adherence to the second
dose of HZ/su (%)
100 90, 70, 50 Assumption
Efficacy HZ/su over time
(linear function)
Function fitted using data from Cunningham
[20], Lal [19] and Curran [47]
Intercept
50–69 years 0.981 0.904 1.057c Normal
≥ 70 years 0.992 0.956 1.028c Normal
Slopeb − 0.041 0.018 0.065 Beta
Efficacy ZVL over time
(one-minus-exponential
function)d
Additional efficacy against
PHN /post-licensure
effectiveness against HZ
Function fitted using data from Oxman [11],
Schmader [46] and Morrison [12]/see
Additional file 1
Intercept − 0.893 − 1.04 − 0.75 Normal
Slope 0.0807 0.058 0.104 Beta
Risk ratio of efficacy
by age
Estimated using Rohan [45] and Schmader
[44]/see Additional file 1
50–59 years 1.282
60–64 years 1.274
65–69 years 1.219
70–74 years 0.852
75–79 years 0.711
80–84 years 0.391
≥ 85 years 0.152
HZ herpes zoster, HZ/su HZ subunit vaccine, PHN post-herpetic neuralgia, QALY quality-adjusted life year, SNPG Stichting Nationaal Programma Grieppreventie, ZVL
zoster vaccine live
aAggregated costs from multiple cost items which were varied individually in the probabilistic sensitivity analysis (see Additional file 1)
bThe slope of 0.009 was only used for 50- to 69-year-olds over the first 4 years covered by the trial. After 4 years, the slope of ≥ 70-year-olds was used
cThe efficacy was rounded to 1 during the period that the efficacy function was above 1
dThe efficacy of ZVL over time (in years) was modelled using a one-minus-exponential function 1 − exp(β1 + β2 × years), in which β1 is the intercept and β2 the
slope. Risk ratios by age were used to modify the intercept. For instance, the efficacy of 60–64 years at time point zero was 1 − exp(1.274 × − 0.893 + 0 × 0.0807) =
67.9%. In our model, we used the VE of the age group 60–64 for vaccination of 60-year-olds, 70–74 for 70-year-olds, 80–84 for 80-year-olds and ≥ 85 years for the
booster for 90-year-olds
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conservatively set the vaccination coverage at 50% of
the total cohort. However, as we used a static model,
the coverage has no impact on the cost-effectiveness
outcomes of vaccination and was only used to esti-
mate the absolute impact of vaccination such as the
number of HZ cases prevented. We assumed that all
HZ/su recipients received two doses of the vaccine
within 2 months and that the coverage of the ZVL
booster after 10 years was 50% of the cohort that
was still alive at that age.
Vaccine efficacy of HZ/su and ZVL against HZ over
time was modelled using data from published clinical
trials (see also Additional file 1: Figure S7) [11, 19,
20, 44–46]. For both vaccines, a function of vaccine
efficacy over the years was fitted to the annual effi-
cacy data using the standard error as a weighting fac-
tor. We fitted multiple types of functions and used
the functions that provided the best fit. For ≥
70-year-olds, a linear function for two doses of HZ/su
was fitted to the 4 years of trial data, resulting in a
waning of 4.1% per year. We assumed that this wan-
ing rate would continue after 4 years and varied this
assumption extensively in the sensitivity analysis. For
50- to 69-year-olds, a recent study estimated the wan-
ing rate at 0.9% per year using unpublished annual
vaccine efficacy estimates [47]. However, no confi-
dence intervals of these estimates were reported, and
the fit of a linear function through the annual vaccine
efficacy estimates was poor. Therefore, we conserva-
tively assumed that this waning rate was only valid
for the first 4 years covered by the trial and would be
equal to the ≥ 70 years age group after 4 years. For
ZVL, a one-minus-exponential function was fitted
using follow-up data of ≥ 60-year-olds up to 11 years
after vaccination [12]. To include the effect of age,
we adjusted the vaccine efficacy at take using
age-specific risk ratios of the clinical trial. For the
ZVL booster, we assumed that the efficacy would be
equal to the efficacy that an initial dose would have
had at that age [26]. More details on the model fits
are provided in Additional file 1.
Effectiveness and cost-effectiveness
The effectiveness of the different HZ vaccination strat-
egies was expressed as the number needed to vaccinate
(NNV) to prevent a HZ case. The cost-effectiveness was
estimated by finding the threshold vaccine cost that
equals an incremental cost-effectiveness ratio (ICER) of
€20,000 per QALY gained [25]. However, as this cost-ef-
fectiveness threshold does not have an official status in
the Netherlands, we also show results for a threshold of
€50,000 per QALY gained. The latter threshold has
been used earlier for pneumococcal vaccination and is
also considered by the Dutch National Health Care
Institute for therapeutic interventions of diseases with a
moderate disease burden that could well be comparable
to PHN [25, 48].
Sensitivity analysis
We performed a probabilistic sensitivity analysis (PSA)
using 10,000 Monte Carlo simulations in which model
inputs were simultaneously varied within their lower and
upper ranges using specified distributions as shown in
Table 1. Lower and upper ranges were estimated using
the 95% CIs of the original sources. The PSA allowed us
to estimate 95% credibility intervals (95% CrI) of the
burden of HZ using the 2.5 and 97.5 percentiles of the
simulations. Additionally, the simulations of the PSA
served as an input for a two-way sensitivity analysis, in
which the vaccine cost per series of HZ/su and per dose
of ZVL were varied at the same time. For each individual
simulation, the total costs and QALYs per alternative
were converted to net monetary benefits (NMBs) using a
cost-effectiveness threshold of €20,000 per QALY gained.
Subsequently, for each combination of cost per series or
dose, we analysed which alternative had the most simu-
lations with the highest NMB and whether this propor-
tion of simulations for the preferred alternative was
above 90% or not.
Additionally, multiple deterministic sensitivity analyses
were performed. The annual waning rate of HZ/su after
4 years was varied between 0 and 10% using a time hori-
zon of 15 years and a lifetime time horizon. We also did
a one-way sensitivity analysis in which model inputs
were varied one-by-one between their lower and upper
ranges while keeping other values at their base case
levels. Finally, several scenario analyses were performed
to explore the impact of different methodological as-
sumptions or inputs from other plausible sources (see
scenario column in Table 1 and Additional file 1 for
more details). These analyses included the use of epi-
demiological input estimates from an immunocompetent
population; a lower adherence to the second dose of
HZ/su of 90%, 70% and 50% relative to the initial dose;
and the attribution of a QALY penalty for vaccine-re-
lated grade 3 adverse events [4, 11, 19, 20, 49]. For ZVL,
we additionally explored the impact of including add-
itional efficacy against PHN as shown in the trial and
the use of vaccine effectiveness data from various
post-licensure studies [11, 14, 16, 50]. For the latter, we
selected three retrospective cohort studies based on the
data from the US Kaiser Permanente Northern Califor-
nia database for the period 2007–2015, the US Medi-
care database for 2007–2014 and UK Clinical Practice
Research Datalink database for 2013–2016, and for
each study, we fitted a linear model (see Additional file 1
for details).
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Reporting quality and model validation
The reporting of the study adheres to the Consoli-
dated Health Economic Evaluation Reporting Stan-
dards (CHEERS) checklist, and the model validation
efforts are reported using the Assessment of the Val-
Idation Status of Health-Economic decision models
(AdVISHE) questionnaire [51, 52]. Both checklists are
added in Additional files 2 and 3.
Results
Current burden of disease
The estimated burden of HZ among the 2017 Dutch
population aged ≥ 50 years is presented in Table 2. The
total number of HZ cases is estimated at 54,169 (95%
CrI 52,130–56,174) per year, resulting in 434 hospital
admissions, 805 1-day hospitalizations, 15 deaths and
3298 PHN cases. This generated a QALY loss of 2992
(95% CrI 2418–3771). The major part of the health bur-
den occurred among 60- to 79-year-olds, while most
deaths were among ≥ 80-year-olds. The total annual cost
burden of HZ was estimated at €19.6 million (95% CrI
16.3–22.6), including €11.3 million healthcare costs and
€7.7 million non-healthcare costs. Most healthcare costs
were due to GP visits, while non-healthcare costs pre-
dominantly consisted of productivity losses among 50-
to 69-year-olds.
Impact of vaccination
The impact of HZ vaccination is presented in Table 3.
For each vaccination age, two doses of HZ/su were esti-
mated to prevent considerably more HZ cases as com-
pared to ZVL single dose or ZVL with a booster after
10 years. Depending on age, vaccination with HZ/su at a
coverage of 50% would avert 4335–10,896 HZ cases
(34.6–37.9% reduction) over the next 15 years, prevent-
ing 318–799 PHN cases, 257–600 lost QALYs and
€0.93–2.40 million on costs to the society. Vaccination
with ZVL would avert 400–4877 HZ cases (3.5–18.0%
reduction) and ZVL with a booster 427–6446 HZ cases
(3.7–27.5% reduction). In absolute terms, the highest
number of cases would be prevented by vaccination of
70-year-olds for HZ/su, while this was 60-year-olds for
ZVL and 50-year-olds for ZVL with a booster. As the
model is static, the number of prevented HZ cases in-
creases linearly with the coverage rate (Additional file 1:
Figure S12). This figure shows that, for instance for
Table 2 Estimated annual burden of herpes zoster in the Netherlands among ≥50-year-olds using January 2017 population data.
The 95%-credibility intervals were based on a probabilistic sensitivity analysis using 10,000 Monte-Carlo simulations
Age group Total 95% CrI− 95% CrI+
50–59 years 60–69 years 70–79 years 80–89 years ≥ 90 years
Population 2,473,222 2,083,983 1,379,744 641,923 121,068 6,699,940
Health outcomes
HZ cases 13,160 16,065 14,772 8557 1614 54,169 52,130 56,174
Hospitalizations 61 101 131 118 22 434 382 489
1-day hospital admissions 88 201 301 181 34 805 734 879
HZ deaths 0 0 1 6 7 15 9 21
PHN cases 289 1179 1084 628 118 3298 2474 4118
LYs lost 4 7 16 39 27 93 56 144
QALYs lost 531 941 873 530 116 2992 2418 3771
Costs (€, millions)
Healthcare costs 2.27 3.50 3.37 1.91 0.23 11.28 9.57 13.43
GP visits, medication, specialist visits 2.08 3.12 2.93 1.70 0.32 10.14 8.49 12.25
Hospitalizations 0.18 0.37 0.48 0.53 0.10 1.66 1.41 1.93
1-day hospital admissions 0.02 0.06 0.08 0.05 0.01 0.23 0.21 0.25
Averted costs due to HZ preterm mortalitya − 0.02 − 0.04 − 0.12 − 0.37 − 0.20 − 0.75 − 1.12 − 0.46
Non-healthcare costs 5.02 2.28 0.25 0.14 0.03 7.73 5.85 9.83
Travel costs 0.14 0.20 0.19 0.11 0.02 0.66 0.54 0.80
OTC medication 0.04 0.07 0.06 0.04 0.01 0.22 0.18 0.26
Productivity loss 4.84 2.01 – – – 7.44 4.99 11.81
Total costs 7.29 5.78 3.62 2.05 0.26 19.59 16.33 24.62
CrI credibility interval, GP general practitioner, HZ herpes zoster, LY life year, OTC over-the-counter, PHN post-herpetic neuralgia, QALY quality-adjusted life year
aAverted healthcare costs due to HZ-related preterm mortality were estimated using the life expectancy and annual treatment costs per year from a standardized
tool [40]
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60-year-olds, vaccination with a series of HZ/su at a
coverage of 24% would avert an equal amount of HZ
cases as vaccination with ZVL at a coverage of 50%.
Effectiveness and cost-effectiveness of vaccination
Two doses of HZ/su was the most effective strategy for
vaccination of 70-year-olds (NNV to prevent a HZ case
of 10.0); however, there was little difference as compared
to 60- and 80-year-old cohorts (NNVs of 10.9 and 10.8)
(Table 3). For ZVL, vaccination age had a considerable
impact on the effectiveness against HZ. The most effect-
ive age of vaccination was 60 years (NNV of 22.8), but
the effectiveness decreased in the older cohorts (NNV of
34.9 for 70 years and 117.0 for 80 years). The effective-
ness of ZVL would improve by adding a booster after
10 years, decreasing the NNV to 17.2 for vaccination
of 60-year-olds, 28.3 for 70-year-olds and 109.5 for
80-year-olds.
The cost-effectiveness showed a similar pattern as
compared to the effectiveness outcomes. For HZ/su, the
maximum vaccine cost per series to remain cost-effect-
ive to a threshold of €20,000 per QALY gained was high-
est for vaccination of 70-year-olds, indicating that this
would be the optimum age of vaccination from a
cost-effectiveness point of view. The threshold vaccine
cost per series at this age was estimated at €109.09. For
ZVL, the highest threshold vaccine cost per dose was
€51.37 for vaccination of 60-year-olds, while adding a
booster dose after 10 years resulted in a decrease of the
threshold cost per dose to €37.79. Our finding that a
ZVL plus a booster had a lower threshold cost per dose
as compared to ZVL single dose was also valid for
shorter periods between the booster and the first dose,
like 5 years. For the vaccination of 80-year-olds, the
threshold vaccine cost per dose of ZVL reached slightly
above €0. The use of a higher cost-effectiveness thresh-
old of €50,000 per QALY gained increased the maximum
vaccine cost allowed considerably. Under this condition,
the threshold cost per series of HZ/su for vaccination of
70-year-olds increased to €274.91.
Table 3 Impact, effectiveness and cost-effectiveness of vaccination of Dutch immunocompetent older adults against HZ at a
coverage of 50% over a period of 15 years. Vaccination strategies include the herpes zoster subunit vaccine (two doses) or zoster
vaccine live (single dose, or single dose + booster after 10 years). Future costs and quality-adjusted life years (QALYs) include an
annual discount rate of 4% and 1.5%, respectively
Vaccination strategy Total
HZ cases
HZ cases
averted
PHN cases
averted
QALYs
gained
Total costs
saved (€, millions)
NNV to
prevent a
HZ case
Threshold vaccine
cost to equal
€20,000 per
QALY (€)a
Threshold vaccine
cost to equal
€50,000 per
QALY (€)a
50 years
No vaccination 22,613
ZVL 18,618 3995 118 159.3 2.060 31.7 29.59 67.29
ZVL + booster 16,392 6220 281 268.1 2.777 20.4 27.09 65.51
HZ/su 14,141 8472 324 351.6 4.026 15.0 63.68 146.91
60 years
No vaccination 27,093
ZVL 22,215 4877 358 266.9 1.698 22.8 51.37 123.23
ZVL + booster 20,627 6466 474 345.5 2.012 17.2 37.79 95.37
HZ/su 16,833 10,260 753 548.9 3.270 10.9 104.30 252.09
70 years
No vaccination 31,481
ZVL 28,368 3113 228 176.9 0.724 34.9 27.48 76.38
ZVL + booster 27,645 3836 281 215.4 0.865 28.3 19.43 58.42
HZ/su 20,585 10,896 799 599.9 2.400 10.0 109.09 274.91
80 years
No vaccination 11,449
ZVL 11,050 400 29 24.7 0.092 117.0 0.73 16.56
ZVL + booster 11,022 427 31 26.4 0.095 109.5 − 1.45 11.69
HZ/su 7114 4335 318 256.6 0.930 10.8 106.03 270.59
HZ herpes zoster, HZ/su herpes zoster subunit vaccine, NNV number needed to vaccinate, PHN post-herpetic neuralgia, QALY quality-adjusted life-year, ZVL zoster
vaccine live (live-attenuated vaccine)
aCost per series (two doses) of HZ/su or cost per dose of ZVL. Administration costs of €11.36 per dose and travel costs of €0.43 per dose are not included
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Sensitivity analyses
A probabilistic two-way sensitivity analysis of the vac-
cine cost per dose of ZVL versus cost per series of HZ/
su is shown in Fig. 1. For each vaccination age, there
were combinations of vaccine cost in which either HZ/
su, ZVL or ZVL with a booster was the most cost-effect-
ive alternative. The competition between HZ/su and
ZVL was the highest for 60-year-olds. For instance, if
the cost per series of HZ/su was assumed at €100, the
maximum cost per dose of ZVL to be the most cost-ef-
fective alternative was estimated €46.75. A ZVL booster
after 10 years had a higher probability of being
cost-effective among 50-year-olds than ZVL single dose
when the cost per dose of ZVL was below €21.25. With
regard to uncertainty, HZ/su had a more than 90% prob-
ability of being the most cost-effective alternative as
Fig. 1 Two-way sensitivity analysis of the vaccine cost per series of HZ/su and vaccine cost per dose of ZVL for vaccination of a 50-year-olds, b
60-year-olds, c 70-year-olds and d 80-year-olds. After performing a probabilistic sensitivity analysis using 10,000 Monte Carlo simulations, the
alternative with the highest probability of being cost-effective to a willingness-to-pay threshold of €20,000 per QALY gained is presented over a
range of vaccine cost. Dark coloured areas indicate that the probability of being the most cost-effective alternative is higher than 90%. HZ/su,
herpes zoster subunit vaccine; QALY, quality-adjusted life year; ZVL, zoster vaccine live
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compared to no vaccination when the vaccine cost per
series would fall below €49.74, €85.80, €83.64 and €87.56
for 50-, 60-, 70- and 80-year-olds, respectively.
Figure 2 shows the impact of the annual waning rate
of HZ/su starting 4 years following vaccination, both
when using a time horizon of 15 years (Fig. 2a, base
case) and when using a lifetime time horizon (Fig. 2b,
sensitivity analysis). Over a period of 15 years, the
threshold vaccine cost per series for vaccination of
70-year-olds with HZ/su would change to €140.44 in
the absence of waning and to €69.18 when a waning
rate of 10% per year was assumed. With regard to the
Fig. 2 Impact of the annual HZ/su waning rate starting 4 years following vaccination on the threshold vaccine cost per series when using a a
time horizon of 15 years or b a lifetime time horizon. The cost-effectiveness threshold was set at €20,000 per quality-adjusted life year gained. HZ,
herpes zoster; HZ/su, herpes zoster subunit vaccine; VE, vaccine efficacy
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optimum vaccination age, 80 years would become the
most cost-effective alternative when the waning rate
was higher than 5.0% per year. Using a lifetime time
horizon, the threshold cost per series of HZ/su in-
creased to €120.94 for vaccination of 70-year-olds at a
waning rate of 4.1% per year as used in the base case
analysis. Furthermore, vaccination of 50- and 60-year-
olds would become more cost-effective as compared to
70- and 80-year-olds when the waning rate would be
lower than 2.3% per year. A sensitivity analysis on the
time horizon shows that after 5 years, the threshold
vaccine cost was €40.39 per series of HZ/su and
€18.88 per dose of ZVL for vaccination of 70-year-olds
(Additional file 1: Figure S13). Figure 3 shows a deter-
ministic sensitivity analysis and a scenario analysis for
HZ/su at vaccination age of 70 years. The deterministic
sensitivity analysis shows that the uncertainty around
the waning rate and parameters involved in the esti-
mation of the QALY loss per HZ episode (probability
of HZ pain, waning of long-term HZ pain and HZ util-
ities) had the highest impact on the cost-effectiveness
(Fig. 3a). The scenario analysis demonstrates that the
threshold vaccine cost per series of HZ/su decreased
to €80.54 when HZ incidence estimates from an im-
munocompetent population were used (Fig. 3b). Re-
duction of the adherence to the second dose of HZ/su
Fig. 3 One-way sensitivity analysis of HZ/su for vaccination of 70-year-olds. The threshold vaccine cost per series is the maximum cost to remain
below a threshold of €20,000 per QALY gained. a Deterministic sensitivity analysis showing the impact of parameter uncertainty by using the
lower (dark grey) and upper (light grey) ranges that were based on the 95% confidence intervals of the input parameters. b Scenario analysis
showing the impact of structural uncertainty by using other plausible model inputs. GP, general practitioner; HC, healthcare; HCP, healthcare
payer; HZ, herpes zoster; HZ/su, herpes zoster subunit vaccine; PHN, post-herpetic neuralgia; QALY, quality-adjusted life year; VE, vaccine efficacy
de Boer et al. BMC Medicine          (2018) 16:228 Page 12 of 18
to 90%, 70% and 50% resulted in lower threshold vac-
cine cost per series of €106.24, €99.54 and €91.05, re-
spectively. The inclusion of a QALY loss due to grade
3 adverse events decreased the threshold vaccine cost
per series to €95.93. The highest impact on the cost-
effectiveness was found for using QALY loss estimates
per HZ case as previously estimated by Van Hoek et
al. [31]. In this scenario, the threshold vaccine cost per
series of HZ/su increased to €248.38. Other scenarios
that altered the threshold vaccine cost by more than
10% included the use of equal discount rates of 4% for
costs and effects, no discounting and the exclusion of
HZ false positives. Deterministic sensitivity analyses
from other age cohorts showed similar results, except
that the exclusion of non-healthcare costs resulted in a
more than 10% decrease of the threshold vaccine cost
per series among 50-year-olds.
Additional scenarios for ZVL included the consider-
ation of additional efficacy against PHN and the use of
post-licensure effectiveness data (Fig. 4). The inclusion
of additional efficacy against PHN increased the thresh-
old vaccine cost for 70- and 80-year-olds to €34.56 and
€6.52, respectively. The use of ZVL effectiveness data re-
sulted in a decrease of the threshold vaccine cost per
dose for 60-year-olds but in a substantial increase for
80-year-olds. For instance, on the basis of 8 years of data
from the US Kaiser Permanente Southern California
database, the threshold vaccine cost per dose of ZVL for
80-year-olds was estimated at €23.64.
Discussion
Our analysis demonstrates that vaccination with two
doses of HZ/su would result in a substantially higher
number of HZ cases prevented and number of QALYs
gained as compared to ZVL (single dose or single dose +
booster). This was explained by the relatively higher effi-
cacy of HZ/su. However, whether vaccination with HZ/
su would be cost-effective as compared to no vaccin-
ation or to ZVL depends largely on the vaccine cost per
series. We found that especially for the 60-year-old co-
hort, there are pricing scenarios in which ZVL could po-
tentially be the most cost-effective alternative. Adding a
ZVL booster after 10 years was expected to reduce the
effectiveness gap between ZVL and HZ/su but required
a significant decrease of the vaccine cost per dose to be
the most cost-effective alternative. The inclusion of add-
itional efficacy against PHN or the use of recent post-li-
censure effectiveness data of ZVL was found to
improve the cost-effectiveness of ZVL among ≥
70-year-olds, increasing the competition between the
two vaccines in these age cohorts.
Implications and possible explanations for findings
A threshold of €20,000 per QALY gained is the general
Dutch cost-effectiveness threshold for healthcare inter-
ventions such as vaccination. At optimum vaccination
age, i.e. 70 years for HZ/su and 60 years for ZVL, the
maximum vaccine costs to remain cost-effective were es-
timated at €109 per series and €51 per dose, respectively.
Fig. 4 Impact of the inclusion of additional efficacy against PHN using trial data and the use of effectiveness data against HZ on the threshold
vaccine cost per dose of ZVL. The cost-effectiveness threshold was set at €20,000 per quality-adjusted life year gained. Effectiveness data from
three data sources, i.e. the US Kaiser Permanente Southern California database [14], the US Medicare database [16] and the UK Clinical Practice
Research Datalink database [50], were explored. For the Medicare and Clinical Practice Research Datalink database, no effectiveness data of 60-
year-olds was available. PHN, post-herpetic neuralgia; QALY, quality-adjusted life year; ZVL, zoster vaccine live
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These estimates are considerably lower than the cur-
rently available vaccine costs of ZVL and HZ/su in the
private sector. For instance, the private sector cost of
two doses of HZ/su would be €226 (US$280) according
to the price list of the Centers for Disease Control and
Prevention, and the private sector cost per dose of ZVL
in the Netherlands is currently €145 [53, 54]. Our model
shows that HZ vaccination would not be cost-effective
with either HZ/su or ZVL when the above-mentioned
vaccine costs are used.
The optimum age of vaccination with HZ/su would be
in the range of 60 to 80 years, as the efficacy is relatively
constant with vaccination age. However, the cost-effect-
iveness and the optimum age of vaccination with HZ/su
were highly sensitive to the duration of protection. Cur-
rently, the waning rate had to be estimated using 4 years
of follow-up data from the trial, showing a decrease in
efficacy over time. However, a closer look to the trial
data by arm shows that the waning of efficacy within the
first 4 years may be caused by a decrease of HZ inci-
dence in the placebo group rather than an increase of
HZ incidence in the vaccinated group [20]. Such a de-
crease of HZ incidence over time in the placebo group is
unexpected because the risk of HZ usually increases
with age. Our sensitivity analysis demonstrated that a
lower waning rate would have a substantial impact on
decision-making, as the optimum age of vaccination
changed from 60 to 80 years to 50–60 years when a life-
time time horizon was used.
Based on the trial data, the optimum vaccination age of
ZVL was 60 years and decreased rapidly with increasing
age. However, sensitivity analyses of ZVL demonstrated
that the cost-effectiveness of ZVL improves substantially
for ≥ 70-year-olds when an additional efficacy against
PHN was taken into account. Post-licensure studies also
confirmed that ZVL was likely to provide additional pro-
tection against PHN as well as to other severe outcomes
like ophthalmic HZ and HZ-related hospitalizations [14,
17, 50, 55]. Moreover, effectiveness studies in the US and
UK found a relatively stable effectiveness of ZVL with in-
creasing age, explaining why in our sensitivity analysis the
cost-effectiveness decreases for 60-year-olds but improves
considerably for 80-year-olds when this data was explored
in our model. This implies that based on trial data only,
the impact of ZVL might be underestimated for the eldest
and that ZVL could be a competitor for HZ/su across all
age groups. However, it should be noted that although ef-
fectiveness studies are more representative for real-life
conditions and have more statistical power due to larger
sample sizes, they can be affected by uncontrolled con-
founders. For instance, observational studies rely on the
healthcare registries and are therefore more likely to
include severe cases as compared to clinical trials that
use active surveillance.
Next to cost-effectiveness, budget impact is often con-
sidered to be important to decision-makers. As most of
the gains are due to the reduction of the burden of
illness, vaccination would increase the total healthcare
expenditure on HZ considerably. In budget impact ana-
lyses, usually a relative short time horizon of maximum
5 years is used and future costs and health effects are
not discounted. Under these conditions, the average an-
nual budget impact of vaccination of 50% of the
60-year-olds would be €6.0 million per year for ZVL
(one-dose schedule) and €12.7 million per year for HZ/
su (two-dose schedule), when corresponding maximum
vaccine costs per series of €51 per dose for ZVL and
€104 for HZ/su were used. This implies that the imple-
mentation of HZ/su would result in a twofold increase
of the total healthcare expenditure on HZ as compared
to ZVL and a more than fourfold increase as compared
to no vaccination.
As HZ/su needs to be administered twice within 2–6
months, vaccination will result in higher healthcare
utilization as compared to ZVL that is given as a single
dose. Moreover, the prospect of a two-dose regimen
might also result in a lower uptake as compared to a
one-dose regimen. But we do also note that HZ/su is
registered for immunocompromised populations as well,
which might be beneficial to the overall vaccination
coverage. Both vaccines can be safely combined with in-
fluenza vaccination [56, 57], which might facilitate the
implementation and save administration costs. However,
influenza vaccination is only given once a year, and
immunogenicity data indicates that revaccination with
HZ/su after 12 months is less immunogenic as com-
pared to 2–6 months after the first dose [58]. Our
sensitivity analysis shows that the adherence to the
second dose of HZ/su impacts the cost-effectiveness
considerably, as a single dose of HZ/su is expected to
have a substantially lower efficacy, especially among
≥ 70-year-olds, and a higher waning rate as compared
to two doses [47].
Safety studies showed that both HZ/su and ZVL were
not associated with serious adverse events among im-
munocompetent older adults but that HZ/su gives a
substantially higher risk of grade 3 adverse events and
local adverse events as compared to ZVL [59]. On the
other hand, vaccination with HZ/su can also reduce the
risk of serious adverse events because post-licensure
studies of ZVL indicate that immunocompromised indi-
viduals were, although its contraindication, occasionally
vaccinated [15, 17]. ZVL can cause serious adverse
events in immunocompromised patients, as it may result
in a symptomatic, progressive infection of the vaccine
virus, causing severe rashes [60].
During the evaluation of ZVL by the Dutch Health
Council in 2016, it was concluded that vaccination
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against HZ did not meet the criteria to be included in
the national immunization programme because it does
not control VZV transmission nor does it prevent sig-
nificant mortality [13]. Vaccination against HZ might
however be indicated for a public programme when the
vaccine would be regarded as essential healthcare due to
a substantial reduction of the individual disease burden
[61]. The Dutch Health Council considered ZVL not as
essential healthcare because of its relatively low efficacy
in the eldest, short duration of protection and the
contraindication for immunocompromised individuals
[13]. Our results demonstrate that HZ/su is expected
to have a significantly higher impact on the health
economic burden of HZ as compared to ZVL (with-
out or with a booster after 10 years), especially among
≥ 70-year-olds.
In our opinion, these results are also of interest to
other countries that are reconsidering HZ vaccination.
Recently, the US Advisory Committee on Immunization
Practices (ACIP) decided to (i) give HZ/su a preferential
status above the ZVL vaccine, (ii) extend the target
group from all immunocompetent ≥ 60-year-olds to all
immunocompetent ≥ 50-year-olds and (iii) revaccinate
individuals that had previously been vaccinated with
ZVL [59]. The UK launched a publicly funded vaccin-
ation programme using ZVL for 70-year-olds with a
catch-up for 78-year-olds in 2013 [62] but now needs to
decide whether vaccination with HZ/su should be pre-
ferred above ZVL, and if so, whether ZVL-vaccinated in-
dividuals should be revaccinated with HZ/su. Since the
UK Joint Committee on Vaccination and Immunisation
recently suggested a similar cost-effectiveness threshold
for vaccines as compared with the Netherlands of
£15,000 (€17,400) per QALY gained [63] and the inci-
dence of HZ tends to be similar across European coun-
tries [64], the HZ/su threshold vaccine cost per series
might be in the same range as we estimated for the
Dutch setting. However, the cost-effectiveness of HZ/su
in a cohort that is vaccinated with ZVL will presumably
be decreased due to a remaining protection offered by
ZVL. For instance, with the use of our model, the
threshold vaccine cost per series of HZ/su among 70-
year-olds decreased from €109.2 per dose to €80.4,
€97.6 and €107.2 per series at 1, 3 and 5 years, respect-
ively, after vaccination with ZVL, when using published
vaccine effectiveness data from the UK [50].
Comparison with other studies
A recent study from the US found that the cost-effect-
iveness of vaccination of 60-year-olds against HZ would
remain below a cost-effectiveness threshold of
US$50,000 (€40,400) per QALY gained when the vaccine
cost per series was below US$360 (€290) for HZ/su and
US$350 (€282) for ZVL [21]. These costs were, after
adjusting for the higher cost-effectiveness threshold,
relatively higher as compared to our findings, which can
be explained by the use of a lifetime time horizon, a
threefold higher healthcare costs per HZ episode and
the inclusion of additional protection against PHN and
burden of illness. With the same model, it was demon-
strated that a HZ/su booster in individuals previously
vaccinated with ZVL would only be cost-effective within
5 years after vaccination if the adherence to the second
dose of HZ/su approached 100% [65]. A public health
impact study for Germany estimated a similar NNV to
prevent a HZ case among ≥ 70-year-olds of 10 for HZ/
su and somewhat higher NNV of 50 for ZVL [47]. A
cost-effectiveness analysis with the same model found
that the ICER of vaccination with HZ/su ranged between
€37,000 and €44,000 per QALY gained when the cost
per series was €220 [22]. A recent study from Italy esti-
mated the cost-effectiveness of ZVL while taking into
account the effect of demographic changes over time
and an accompanying varicella vaccination programme
[5]. They found that the incidence of HZ is expected to
increase over the next decades due to the ageing of the
population, that varicella vaccination might cause a fur-
ther increase of the incidence of HZ because of the re-
duction of exogenous boosting and that HZ vaccination
would cost-effectively reduce this increasing burden of
HZ. Finally, two earlier Dutch studies assessing the
cost-effectiveness of ZVL estimated ICERs of €22,000
per QALY gained and €30,000 per QALY gained for
70-year-olds using vaccine cost per dose of €77 and €87,
respectively [66, 67]. The most important explanation
for finding a relatively lower threshold cost per dose in
our current study was a substantially lower QALY loss
per HZ case. Some other differences were the use of
updated HZ incidence rates and long-term efficacy data
of ZVL.
Strengths and limitations
The main strength of our study is that we were able to
combine high-quality vaccine efficacy data from large
clinical trials with HZ burden estimates from national
data sources. HZ incidence was obtained from a GP net-
work that has been validated as a good representation of
the general Dutch population. Cost and QALY loss esti-
mates were obtained from a large Dutch prospective co-
hort study with a long-term follow-up period of 12
months after onset and using the validated EQ-5D in-
strument to estimate HR-QoL. Moreover, we included a
vaccination alternative of ZVL with a booster in our ana-
lysis, which has not been compared with HZ/su so far
and we are the first exploring post-licensure effective-
ness data of ZVL in a cost-effectiveness model.
Our analysis also has its limitations. The duration of
protection of HZ/su is currently unknown, which
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appeared to be an important parameter in the sensitivity
analysis. Next, data on adherence to the second dose of
HZ/su and the efficacy and waning of one dose of HZ/
su is scarce, which also was shown to have an impact on
the cost-effectiveness. Also, applying data from the total
Dutch population on immunocompetent cohorts might
have led to an overestimation of the impact of vaccin-
ation. However, we performed a sensitivity analysis by
adjusting the epidemiological parameters for this aspect.
The patient recruitment and data acquisition of the pro-
spective cohort study that was mainly used for the esti-
mation of HZ-related costs and QALY losses were partly
web-based, which might have introduced a selection bias
due to the inclusion of healthier subjects able to under-
stand and fill out a web-based questionnaire. However,
the target group in our model consisted of immunocom-
petent individuals, which might also represent a health-
ier cohort than the general population. Finally, rare HZ-
related complications like monaural deafness and mon-
ocular blindness were not included in our model.
Future recommendations
For the future, we recommend an update of our analysis
when long-term efficacy data of HZ/su become available.
Currently, the long-term duration of protection of HZ/
su is investigated in a subpopulation of the trial, while
also the impact of revaccination with one or two doses
of HZ/su will be assessed [68]. Next, we would recom-
mend cost-effectiveness studies specifically for immuno-
compromised populations. Recent non-peer-reviewed
results of HZ/su for autologous haematopoietic stem cell
transplant recipients showed that HZ/su was 68.2% (95%
CI 55.6–77.5) efficacious against HZ, while no safety is-
sues occurred [69]. As the risk of HZ among autologous
haematopoietic stem cell transplant recipients has been
estimated at 16–31% within the first year after trans-
plantation [70], vaccination of such a target group might
potentially result in improved cost-effective outcomes as
compared to vaccination of immunocompetent individ-
uals only.
Conclusions
Two doses of HZ/su was found to be superior in redu-
cing the burden of HZ among Dutch immunocompetent
older adults as compared to ZVL single dose or ZVL
single dose with a booster after 10 years. Vaccination
could potentially be cost-effective for both HZ/su and
ZVL in the context of the conventional Dutch cost-ef-
fectiveness threshold of €20,000 per QALY gained, but
this depends largely on the vaccine cost. It is anticipated
that these results will be useful for policy-makers in the
Netherlands and in all other countries considering HZ
vaccination.
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Kingdom; US: United States; VZV: Varicella-zoster virus; ZVL: Zoster vaccine live
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